A. Paravisini

TL;DR: Patients with rheumatoid arthritis have an increased risk of cardiovascular disease that may not always be related to the presence of traditional cardiovascular risk factors, but patients who had positive anti-CCP antibodies experienced more frequent ischemic heart disease.

TL;DR: A proposed sequential therapeutic strategy with 2 monoclonal antibodies, omalizumab and rituximab, which might induce clinical benefit with few side effects in selected individuals with severe Atopic dermatitis might be a good alternative for patients with severe AD.

TL;DR: Omalizumab is a well-tolerated and safe drug that can be useful for the treatment of severe atopic dermatitis refractory to at least 2 systemic drugs and opens the door to the management of atopy dermatitis using systemic immunomodulating therapies.

TL;DR: Pigmented Paget’s disease of the male breast in a man without underlying breast carcinoma and a collective review and a case report are published.

TL;DR: Good control of the skin disease was achieved with omalizumab in monotherapy in 2 patients, and there was a slight improvement in the eczematous lesions in 4 patients.